中國健康科技集團(01069.HK):聯交所譴責公司兩名前董事
格隆匯5月28日丨中國健康科技集團(01069.HK)公告,聯交所向下列人士作出董事不適合性聲明及譴責:(1)該公司前執行董事王嶽先生;及(2)該公司前獨立非執行董事田光梅女士。董事不適合性聲明是指聯交所認爲,王嶽先生及田女士均不適合擔任該公司或其任何附屬公司的董事或高級管理階層成員。
王嶽先生就有關貸款違反了《上市規則》第3.08條。王嶽先生及田女士就出售事項違反了《上市規則》第3.08條,且未有履行現載於《上市規則》第3.09C(2)條的責任,因其未有在上市科的調查中給予合作。二人的行爲相當於嚴重違反他們在《上市規則》下的責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.